Company intelligence / Profile preview

Molecular Partners AG

Schlieren, Zürich, Switzerlandfinance.yahoo.com ↗

Ownership: Public · MOLN
Employees: ~152
Development stage: Phase 1

Overview

Molecular Partners is developing DARPin therapeutics with applications in oncology, immuno-oncology, ophthalmology, and infectious diseases. Their lead candidates include MP0712 (DLL3-Radio-DARPin Therapy) for SCLC and neuroendocrine tumors, MP0274 (targeting Her2) in Phase 1, and MP0310 (FAP x 4-1BB) in Phase 1 in collaboration with Amgen.

Therapeutic areas: OphthalmologyOncologyInfectious Diseases
Modalities: DARPin therapeuticsRadio-DARPin Therapy (RDT)Switch-DARPin Platform
Industry: Biotech

Drug pipeline

16 assets

abicipar pegol

15 more assets in the full pipeline.

Request access →

Partnerships

Orano MedAmgenAllergan

Financials

Market cap: $164.3M
Total revenue: $0
Enterprise value: $99.6M

Beyond the preview

Go deeper on Molecular Partners AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular Partners AG.

Explore the full profile